MIM
JNCE

Monashee Investment Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Monashee Investment Management’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-17,773
Closed -$249K – 125
2017
Q2 		$249K Buy
+17,773
New +$380K 0.11% 79
2017
Q1 		– Hold
0
– – – 73

Other funds holding JNCE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Monashee Investment Management's JNCE Position: Q3 2017 in Review

Monashee Investment Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q3 2017, closing a stake of 17,773 shares — an estimated $249K sold.

Monashee Investment Management first reported a position in JNCE in Q2 2017 and held it in 1 quarter. The position peaked at $249K in Q2 2017. 76 funds tracked by Wall St. Rank hold JNCE as of Q3 2017.

  • Monashee Investment Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Monashee Investment Management sold 17,773 Jounce Therapeutics, Inc. Common Stock shares in Q3 2017, an estimated $249K.
  • Monashee Investment Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2017 and held it in 1 quarter.
  • Monashee Investment Management's Jounce Therapeutics, Inc. Common Stock position peaked at $249K in Q2 2017.
  • 76 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2017.

Based on Monashee Investment Management's 13F filing for Q3 2017, filed 13 Nov 2017.